Results 161 to 170 of about 39,906 (300)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Exploring Giant Barium Stars:12C/13C Ratio and Elemental Abundances of Carbon, Nitrogen, and Oxygen

The Astronomical Journal
Barium (Ba) stars belong to binary systems that underwent mass-transfer events. As a consequence, their envelopes were enriched with material synthesized in the interiors of their evolved companions via slow neutron-capture nucleosynthesis, the s ...
M. P. Roriz, N. A. Drake, N. Holanda, M. Lugaro, B. Cseh, S. Junqueira, C. B. Pereira   +6 more
doaj   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Lithium Abundances from the LAMOST Medium-resolution Survey Data Release 9

The Astrophysical Journal Supplement Series
Lithium is a fragile but crucial chemical element in the Universe, and exhibits interesting and complex behaviors. Thanks to the mass of spectroscopic data from the Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST) medium-resolution ...
Ming-Yi Ding, Jian-Rong Shi, Hong-liang Yan, Chun-Qian Li, Qi Gao, Tian-Yi Chen, Jing-Hua Zhang, Shuai Liu, Xiao-Jin Xie, Yao-Jia Tang, Ze-Ming Zhou, Jiang-Tao Wang   +11 more
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

SDSS J0018-0939: A Clear Signature of Sub-Chandrasekhar Mass Type 1a Supernova

The Astrophysical Journal
Very metal-poor (VMP) stars ([Fe/H] ≤ −2) that have subsolar values of [X/Fe] for α elements such as Mg, Si, and Ca, are referred to as α -poor VMP stars.
S. K. Jeena, Projjwal Banerjee
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Overview of the LAMOST survey in the first decade. [PDF]

Innovation (Camb), 2022
Yan H, Li H, Wang S, Zong W, Yuan H, Xiang M, Huang Y, Xie J, Dong S, Yuan H, Bi S, Chu Y, Cui X, Deng L, Fu J, Han Z, Hou J, Li G, Liu C, Liu J, Liu X, Luo A, Shi J, Wu X, Zhang H, Zhao G, Zhao Y.   +26 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source